| NCT01695473 |
Febbo UCSF/Novartis |
PI3K |
BKM-120 |
Quantification of phospho-S6, phospho-AKT, phospho-4EBP1, and PSA response |
| NCT00526591 |
Garcia case Comprehensive Cancer Center |
mToR |
Everolimus |
Rates of pCR, extracapsular extension; margin status, toxicity, PSADT, and IHC for intraprostatic biomarkers |
| NCT00138918 |
Chi University of British Columbia/Department of Defense |
Clusterin |
oGX-011 |
Rate of pCR, quantify intraprostatic expression of clusterin, oGX-011; associate oGX-011 with PBMNC and serum clusterin |
| NCT00589472 |
Slovin NCI |
HDAC |
Vorinostat |
Rate of pCR, before and after levels of testosterone, DHT, DHEA, and DHEA-S in prostate tissue; gene and expression analysis of AR genes, PSA, and TMPRSS2 |
| NCT01832259 |
Agarwal University of Utah |
VEGFR |
Pazopanib |
Decrease premetastatic niche (LN disease), PFS, and toxicity |
| NCT01409200 |
Zurita MD Anderson/Pfizer |
VEGFR |
Axitinib |
PFS |
| NCT01385059 |
Pal City of Hope |
VEGFR |
Axitinib |
Premetastatic niche density: quantitate VEGFR1 clusters, pSTAT3, MDSC, LoX, angiogenic factors, and bPFS |
| NCT00329043 |
Zurita MD Anderson/Pfizer |
VEGFR |
Sunitinib |
Rate of pCR |
| NCT00321646 |
Taplin lBIDMC, Duke, Genentech, Sanofi |
VEGF |
Bevacicumab + docetaxel |
Efficacy, safety |
| NCT00715104 |
Fong Dendreon/UCSF |
Dendritic cells |
Sip-T |
Intraprostatic T-cell infiltration |
| NCT00305669 |
Fong UCSF/NCI |
Immune |
GM-CSF |
Intraprostatic T-cell and dendritic cell infiltration |
| NCT01194271 |
Sharma MD Anderson |
Immune |
Ipilimumab + ADT |
Tumor and blood effector to regulatory T-cell ratio, CD4+ICoS+ T cells, CD8+ICoS+ T cells, NY-ESo-1 antibodies (only in blood), and absolute lymphocyte count (only in blood) |
| NCT00400517 |
Dreicer, Klein Cleveland Clinic |
Immune |
GM-CSF + Thalidomide |
Rates of pCR, negative surgical margins, PSA response, and PFS |
| NCT01696877 |
Antonarakis Sidney Kimmel Comprehensive Cancer Center |
Immune |
GVAX |
Intraprostatic CD8+ T-cell infiltration, intraprostatic CD4+ T-cell and Treg infiltration, quantification of tissue androgens and markers of apoptosis, serum antibodies to prostatic antigens, rate of pCR and PSA response, and PFS |
| NCT01804712 |
Howell Genentech |
CD-20 |
Rituximab |
Histologic response rate, change in: PSA, peripheral blood B cell count, and serum CXCL13 level |
